Nutan Marathi Higher Secondary School in Paharganj in Delhi is championing the cause of teaching Marathi in the national ...

ThreatLocker is extending its platform to new security categories while bringing its ‘deny-by-default’ approach deeper into ...

The modernization of the Ninoy Aquino International Airport (NAIA) was adjudged Transport Deal of the Year at the Project Finance International (PFI) Asia Pacific Awards in London on Feb. 20. “More ...

THE government is on track to achieve its target of delivering 500,000 affordable houses (RMM) by year-end, says Housing and ...

新年伊始，乘风出海。就在近日，江北新区企业驯鹿生物有一则好消息传来：香港卫生署已正式受理其CAR-T细胞产品伊基奥仑赛注射液（FUCASO）的新药上市许可申请，用于治疗既往经过至少3线治疗后进展的复发/难治性多发性骨髓瘤（R/RMM）成人患者。

As part of N-able's Tech Alliance Partner Ecosystem, Xurrent's integration provides a seamless experience for MSPs looking to elevate their IT service management capabilities. The integration ...

日前，江北新区南京生物医药谷园区企业驯鹿生物宣布，中国香港卫生署已正式受理其CAR-T细胞产品伊基奥仑赛注射液（FUCASO）的新药上市许可申请（NDA)，用于治疗既往经过至少3线治疗后进展的复发/难治性多发性骨髓瘤（R/RMM）成人患者。

The window for intrusion detection keeps getting shorter as ransomware group’s time-to-ransom (TTR) accelerates.

本报讯（许雯斐唐洋洋）2月14日，南京江北新区药企驯鹿生物宣布，香港卫生署已正式受理其CAR-T细胞产品伊基奥仑赛注射液的新药上市许可申请（NDA)，用于治疗既往经过至少3线治疗后进展的复发难治性多发性骨髓瘤（RRMM）成人患者。

2月16日，证券时报记者从南京江北新区获悉，新区生物医药企业驯鹿生物日前宣布，香港卫生署已正式受理其CAR-T细胞产品伊基奥仑赛注射液（FUCASO）的新药上市许可申请（NDA)，用于治疗既往经过至少3线治疗后进展的复发/难治性多发性骨髓瘤（R/RMM）成人患者。这是香港卫生署首次正式受理国产CAR-T细胞产品的新药上市申请。

关注我哟定期推送帐号信息学新闻，竞赛自主招生，信息学专业知识，信息学疑难解答，信息学训练营信息等诸多优质内容的微信平台， 欢迎分享文章给你的朋友或者朋友圈！ 有任何问题请联系小编！